Atara Biotherapeutics (NASDAQ:ATRA) Releases Earnings Results, Beats Expectations By $2.63 EPS

Atara Biotherapeutics (NASDAQ:ATRA) released its earnings results on Friday. The biotechnology company reported ($1.19) EPS for the quarter, topping analysts’ consensus estimates of ($3.82) by $2.63, Zacks reports. The company had revenue of $32.75 million during the quarter, compared to analysts’ expectations of $20.58 million.

Atara Biotherapeutics Stock Performance

ATRA stock opened at $6.90 on Friday. Atara Biotherapeutics has a fifty-two week low of $5.40 and a fifty-two week high of $20.81. The business’s 50-day moving average is $9.74 and its two-hundred day moving average is $9.73. The company has a market cap of $39.74 million, a price-to-earnings ratio of -0.27 and a beta of 0.49.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on the company. RODMAN&RENSHAW cut Atara Biotherapeutics from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, January 21st. Canaccord Genuity Group lowered their price target on Atara Biotherapeutics from $21.00 to $17.00 and set a “buy” rating on the stock in a report on Friday, January 17th. HC Wainwright reaffirmed a “neutral” rating on shares of Atara Biotherapeutics in a report on Tuesday, January 28th. TD Cowen raised Atara Biotherapeutics to a “strong-buy” rating in a report on Friday, November 29th. Finally, Rodman & Renshaw assumed coverage on Atara Biotherapeutics in a report on Friday, December 20th. They set a “buy” rating and a $25.00 price target on the stock. One analyst has rated the stock with a sell rating, three have given a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $17.75.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.